Combination Therapy With MET Tyrosine Kinase Inhibitor and EGFR Tyrosine Kinase Inhibitor in Patients With MET-Overexpressed EGFR-Mutant Lung Adenocarcinoma by Jia-Jun Wu, MD, Zhe-Rong Zheng, MD, Tse-Hsien Lo, MD, Cheng-Hsiang Chu, MD, Kun-Chieh Chen, MD, PhD, Gee-Chen Chang, MD, PhD

Get full text